MedTrace Logo

Bioavailability Study of Ondansetron Orally Disintegrating Tablets Under Fed Conditions

NCT00653458 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2008-04-11

No results posted yet for this study

Summary

To compare the single-dose bioavailability of Ondansetron ODT 8 mg and Zofran 8 mg

Conditions

  • Healthy

Interventions

DRUG

Ondansetron

ODT, 8 mg, single-dose, fed conditions

DRUG

Zofran

ODT, 8 mg, single-dose, under fed conditions

Sponsors & Collaborators

  • Algorithme Pharma Inc

    collaborator INDUSTRY

  • Par Pharmaceutical, Inc.

    lead INDUSTRY

Principal Investigators

  • Christian Aumais · Algotithme Pharma Inc

Study Design

Allocation
RANDOMIZED
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2002-08-31
Primary Completion
2002-09-30
Completion
2002-09-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00653458 on ClinicalTrials.gov